Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 12.25
(4.08%)
CNY 12.25
(4.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 840.85 Million CNY | 63.72% |
| 2022 | 606.16 Million CNY | -34.28% |
| 2021 | 736.63 Million CNY | -3.82% |
| 2020 | 842.75 Million CNY | 1.46% |
| 2019 | 813.61 Million CNY | 0.78% |
| 2018 | 753.35 Million CNY | 0.22% |
| 2017 | 837.58 Million CNY | 3.51% |
| 2016 | 802.72 Million CNY | -7.13% |
| 2015 | 856.7 Million CNY | 24.7% |
| 2014 | 712.51 Million CNY | 8.37% |
| 2013 | 622.72 Million CNY | 20.56% |
| 2012 | 538.7 Million CNY | 28.83% |
| 2011 | 424.25 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 481.25 Million CNY | 106.05% |
| 2024 Q2 | 182.32 Million CNY | -46.14% |
| 2024 Q3 | -17.93 Million CNY | -108.33% |
| 2023 Q1 | 361.98 Million CNY | 265.35% |
| 2023 Q4 | 193.97 Million CNY | 7.43% |
| 2023 Q3 | 180.55 Million CNY | 1507.39% |
| 2023 Q2 | -12.82 Million CNY | -103.54% |
| 2023 FY | - CNY | 63.72% |
| 2022 Q4 | 99.07 Million CNY | 191.01% |
| 2022 Q2 | 161.1 Million CNY | -32.31% |
| 2022 Q3 | -108.86 Million CNY | -167.57% |
| 2022 FY | - CNY | -34.28% |
| 2022 Q1 | 238 Million CNY | 1.64% |
| 2021 Q1 | 205.52 Million CNY | -9.54% |
| 2021 Q3 | 38.82 Million CNY | -83.4% |
| 2021 Q4 | 234.17 Million CNY | 503.22% |
| 2021 FY | - CNY | -3.82% |
| 2021 Q2 | 233.88 Million CNY | 13.8% |
| 2020 Q2 | 180.2 Million CNY | -9.65% |
| 2020 Q4 | 227.21 Million CNY | 88.6% |
| 2020 Q1 | 199.45 Million CNY | 19.28% |
| 2020 Q3 | 120.47 Million CNY | -33.15% |
| 2020 FY | - CNY | 1.46% |
| 2019 FY | - CNY | 0.78% |
| 2019 Q1 | 223.41 Million CNY | -0.82% |
| 2019 Q2 | 218.57 Million CNY | -2.17% |
| 2019 Q4 | 167.21 Million CNY | 36.04% |
| 2019 Q3 | 122.92 Million CNY | -43.76% |
| 2018 FY | - CNY | 0.22% |
| 2018 Q4 | 225.26 Million CNY | 26.7% |
| 2018 Q3 | 177.79 Million CNY | 19.81% |
| 2018 Q2 | 148.39 Million CNY | -21.87% |
| 2018 Q1 | 189.93 Million CNY | -4.63% |
| 2017 Q1 | 147.64 Million CNY | -39.75% |
| 2017 FY | - CNY | 3.51% |
| 2017 Q4 | 199.16 Million CNY | -21.56% |
| 2017 Q3 | 253.9 Million CNY | 53.14% |
| 2017 Q2 | 165.8 Million CNY | 12.3% |
| 2016 FY | - CNY | -7.13% |
| 2016 Q4 | 245.06 Million CNY | 46.55% |
| 2016 Q3 | 167.21 Million CNY | -18.48% |
| 2016 Q2 | 205.12 Million CNY | 107.72% |
| 2016 Q1 | 98.75 Million CNY | -74.17% |
| 2015 Q1 | 45.78 Million CNY | -84.04% |
| 2015 Q2 | 272.34 Million CNY | 494.79% |
| 2015 FY | - CNY | 24.7% |
| 2015 Q4 | 382.33 Million CNY | 458.65% |
| 2015 Q3 | 68.43 Million CNY | -74.87% |
| 2014 Q3 | 18.7 Million CNY | -93.7% |
| 2014 FY | - CNY | 8.37% |
| 2014 Q4 | 286.97 Million CNY | 1434.1% |
| 2014 Q2 | 297.03 Million CNY | 1331.01% |
| 2014 Q1 | 20.75 Million CNY | 0.0% |
| 2013 FY | - CNY | 20.56% |
| 2012 FY | - CNY | 28.83% |
| 2011 FY | - CNY | 0.0% |